Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

BioAge Labs (BIOA) Financials

BioAge Labs logo
$16.72 +0.61 (+3.81%)
As of 11:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for BioAge Labs

Annual Income Statements for BioAge Labs

This table shows BioAge Labs' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -64 -71 -81
Consolidated Net Income / (Loss)		 -64 -71 -81
Net Income / (Loss) Continuing Operations		 -64 -71 -80
Total Pre-Tax Income 		-64 -71 -80
Total Operating Income		 -48 -78 -93
Total Gross Profit		 0.00 0.00 9.00
Total Revenue		 0.00 0.00 9.00
Operating Revenue		 - 0.00 9.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 48 78 102
Selling, General & Admin Expense		 15 19 28
Research & Development Expense		 34 59 74
Total Other Income / (Expense), net		 -15 7.01 12
Interest Expense		 7.79 2.62 0.70
Interest & Investment Income		 2.43 9.63 13
Basic Earnings per Share		 ($38.17) ($6.63) ($2.24)
Weighted Average Basic Shares Outstanding		 1.67M 10.73M 35.93M
Diluted Earnings per Share		 ($38.17) ($6.63) ($2.24)
Weighted Average Diluted Shares Outstanding		 1.67M 10.73M 35.93M
Weighted Average Basic & Diluted Shares Outstanding		 - 35.85M 44.38M

Quarterly Income Statements for BioAge Labs

This table shows BioAge Labs' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -15 -13 -14 -23 -21 -13 -22 -20 -26 -22
Consolidated Net Income / (Loss)		 -15 -13 -14 -23 -21 -13 -22 -20 -26 -22
Net Income / (Loss) Continuing Operations		 -15 -13 -14 -23 -21 -13 -22 -20 -26 -22
Total Pre-Tax Income 		-15 -13 -14 -23 -21 -13 -22 -20 -26 -22
Total Operating Income		 -9.89 -13 -15 -25 -25 -16 -25 -23 -28 -25
Total Gross Profit		 0.00 0.00 0.00 0.00 - 1.45 2.41 2.05 3.08 2.77
Total Revenue		 0.00 0.00 0.00 0.00 - 1.45 2.41 2.05 3.08 2.77
Operating Revenue		 - 0.00 0.00 0.00 - 1.45 2.41 2.05 3.08 2.77
Total Cost of Revenue		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 9.89 13 15 25 25 18 27 25 32 28
Selling, General & Admin Expense		 3.36 3.49 4.80 4.73 6.14 6.79 7.34 6.68 7.00 7.74
Research & Development Expense		 6.53 9.32 10 20 19 11 20 19 25 20
Total Other Income / (Expense), net		 -4.74 -0.17 1.76 1.34 4.08 3.46 3.22 3.01 2.70 3.23
Interest Expense		 2.40 1.47 0.44 0.39 0.32 0.26 0.20 0.15 0.09 0.04
Interest & Investment Income		 0.50 1.30 2.20 2.04 4.10 3.71 3.42 3.16 2.79 3.27
Basic Earnings per Share		 ($8.74) ($7.76) ($7.94) ($6.70) $15.77 ($0.36) ($0.60) ($0.56) ($0.72) ($0.52)
Weighted Average Basic Shares Outstanding		 1.67M 1.67M 1.71M 3.49M 10.73M 35.85M 35.85M 35.85M 35.93M 42.48M
Diluted Earnings per Share		 ($8.74) ($7.76) ($7.94) ($6.70) $15.77 ($0.36) ($0.60) ($0.56) ($0.72) ($0.52)
Weighted Average Diluted Shares Outstanding		 1.67M 1.67M 1.71M 3.49M 10.73M 35.85M 35.85M 35.85M 35.93M 42.48M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 35.85M 35.85M 35.85M 35.85M 35.86M 44.38M 44.45M

Annual Cash Flow Statements for BioAge Labs

This table details how cash moves in and out of BioAge Labs' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -2.69 329 -165
Net Cash From Operating Activities		 -37 -52 -82
Net Cash From Continuing Operating Activities		 -37 -52 -82
Net Income / (Loss) Continuing Operations		 -64 -71 -81
Consolidated Net Income / (Loss)		 -64 -71 -81
Depreciation Expense		 0.16 0.17 0.21
Amortization Expense		 - 0.00 -1.62
Non-Cash Adjustments To Reconcile Net Income		 20 8.24 12
Changes in Operating Assets and Liabilities, net		 6.71 11 -12
Net Cash From Investing Activities		 -0.27 -0.37 -95
Net Cash From Continuing Investing Activities		 -0.27 -0.37 -95
Purchase of Property, Plant & Equipment		 -0.17 -0.37 -0.72
Purchase of Investments		 -0.10 0.00 -155
Sale and/or Maturity of Investments		 - 0.00 60
Net Cash From Financing Activities		 35 381 11
Net Cash From Continuing Financing Activities		 35 381 12
Repayment of Debt		 -1.06 -6.00 -6.34
Repurchase of Common Equity		 - -0.54 0.00
Issuance of Preferred Equity		 0.00 170 0.00
Issuance of Common Equity		 0.00 222 17
Other Financing Activities, net		 0.00 0.63 0.71
Effect of Exchange Rate Changes		 - - -0.09
Cash Interest Paid		 1.16 1.42 0.61

Quarterly Cash Flow Statements for BioAge Labs

This table details how cash moves in and out of BioAge Labs' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -9.51 152 -18 175 20 -97 -37 -4.76 -27 53
Net Cash From Operating Activities		 -8.50 -16 -16 -15 -5.14 -17 -20 -16 -28 -24
Net Cash From Continuing Operating Activities		 -8.50 -15 -16 -15 -5.14 -17 -20 -16 -28 -24
Net Income / (Loss) Continuing Operations		 -21 -13 -14 -23 -21 -13 -22 -20 -26 -22
Consolidated Net Income / (Loss)		 -21 -13 -14 -23 -21 -13 -22 -20 -26 -22
Depreciation Expense		 0.04 0.03 0.05 0.04 0.05 0.04 0.06 0.05 0.07 0.06
Amortization Expense		 - - - - - 0.00 - - - -0.31
Non-Cash Adjustments To Reconcile Net Income		 7.89 2.27 1.41 2.21 2.36 2.94 3.30 2.84 2.98 4.44
Changes in Operating Assets and Liabilities, net		 4.53 -4.70 -3.94 6.23 14 -7.53 -1.79 1.23 -3.74 -5.99
Net Cash From Investing Activities		 - 0.00 -0.04 -0.31 -0.03 -78 -16 13 -14 -47
Net Cash From Continuing Investing Activities		 - 0.00 -0.04 -0.31 -0.03 -78 -16 13 -14 -47
Purchase of Property, Plant & Equipment		 - 0.00 -0.04 -0.31 -0.03 -0.43 -0.16 -0.02 -0.11 -0.03
Purchase of Investments		 - 0.00 - - - -78 -24 -13 -40 -80
Sale and/or Maturity of Investments		 - 0.00 - - - 0.00 8.50 26 26 33
Net Cash From Financing Activities		 -1.01 168 -2.39 191 25 -1.50 -1.50 -1.54 16 124
Net Cash From Continuing Financing Activities		 -1.01 168 -2.39 191 25 -1.50 -1.50 -1.54 16 124
Repayment of Debt		 -1.01 -1.50 -2.77 -3.50 1.77 -1.50 -1.50 -1.54 -1.79 -1.59
Repurchase of Preferred Equity		 - - - - - - - - - 0.00
Repurchase of Common Equity		 - -0.50 - - - 0.00 - - - -0.72
Issuance of Preferred Equity		 - 170 - - - 0.00 - - - 0.00
Issuance of Common Equity		 - 0.00 -0.54 195 28 0.00 - - 17 124
Other Financing Activities, net		 0.00 0.00 0.42 0.18 0.03 0.00 - - 0.71 1.71
Cash Interest Paid		 0.47 0.43 0.38 0.34 0.28 0.22 0.18 0.13 0.09 0.04

Annual Balance Sheets for BioAge Labs

This table presents BioAge Labs' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 26 358 295
Total Current Assets		 25 357 287
Cash & Equivalents		 22 354 189
Restricted Cash		 3.31 - 0.00
Short-Term Investments		 - 0.00 92
Accounts Receivable		 - 0.00 0.77
Prepaid Expenses		 0.35 2.75 4.93
Plant, Property, & Equipment, net		 0.32 0.59 0.96
Total Noncurrent Assets		 0.30 0.54 7.13
Long-Term Investments		 0.10 0.10 0.10
Other Noncurrent Operating Assets		 0.20 0.44 7.03
Total Liabilities & Shareholders' Equity		 26 358 295
Total Liabilities		 67 35 23
Total Current Liabilities		 58 28 20
Short-Term Debt		 27 6.00 2.65
Accounts Payable		 1.87 2.00 2.67
Accrued Expenses		 7.94 12 8.48
Current Deferred Revenue		 3.31 7.83 5.75
Other Current Liabilities		 18 0.20 0.58
Total Noncurrent Liabilities		 8.43 7.33 2.70
Long-Term Debt		 8.20 2.50 0.00
Noncurrent Deferred Revenue		 0.00 4.67 0.00
Other Noncurrent Operating Liabilities		 0.23 0.16 2.70
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -173 323 272
Total Preferred & Common Equity		 -173 323 272
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 -173 323 272
Common Stock		 8.14 576 605
Retained Earnings		 -182 -253 -333
Accumulated Other Comprehensive Income / (Loss)		 0.16 0.25 0.28

Quarterly Balance Sheets for BioAge Labs

This table presents BioAge Labs' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 337 344 322 305 398
Total Current Assets		 336 325 302 291 392
Cash & Equivalents		 334 257 220 216 242
Restricted Cash		 0.00 0.00 0.00 0.00 0.00
Short-Term Investments		 - 63 77 70 143
Accounts Receivable		 - 0.36 0.60 0.52 0.71
Prepaid Expenses		 1.99 3.93 3.80 4.54 7.96
Plant, Property, & Equipment, net		 0.54 0.93 0.97 0.97 1.12
Total Noncurrent Assets		 0.37 18 19 13 3.00
Long-Term Investments		 0.10 0.10 0.10 0.10 0.10
Other Noncurrent Operating Assets		 0.27 18 19 13 2.90
Total Liabilities & Shareholders' Equity		 337 344 322 305 398
Total Liabilities		 24 31 27 28 19
Total Current Liabilities		 19 24 23 24 16
Short-Term Debt		 6.00 6.00 5.60 4.13 1.16
Accounts Payable		 2.10 3.99 1.33 5.02 3.07
Accrued Expenses		 11 4.87 7.58 7.26 4.77
Current Deferred Revenue		 0.00 8.18 7.70 7.51 6.19
Other Current Liabilities		 0.27 0.70 0.63 0.58 0.65
Total Noncurrent Liabilities		 4.55 6.94 4.53 3.13 2.71
Long-Term Debt		 3.94 1.06 0.00 0.00 0.00
Noncurrent Deferred Revenue		 - 3.23 1.90 0.56 0.00
Other Noncurrent Operating Liabilities		 0.61 2.65 2.63 2.58 2.71
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 314 313 295 277 379
Total Preferred & Common Equity		 314 313 295 277 379
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 314 313 295 277 379
Common Stock		 545 579 582 585 735
Retained Earnings		 -232 -266 -287 -307 -356
Accumulated Other Comprehensive Income / (Loss)		 0.11 0.26 0.21 0.28 0.07

Annual Metrics And Ratios for BioAge Labs

This table displays calculated financial ratios and metrics derived from BioAge Labs' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 35,848,738.00 35,855,037.00
DEI Adjusted Shares Outstanding		 0.00 35,848,738.00 35,855,037.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.98 -2.25
Growth Metrics		 - - -
Profitability Metrics		 - - -
Net Operating Profit after Tax (NOPAT)		 -34 -55 -65
Return On Investment Capital (ROIC_SIMPLE)		 24.46% -16.51% -23.64%
Earnings before Interest and Taxes (EBIT)		 -58 -78 -93
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -58 -78 -94
Valuation Ratios		 - - -
Leverage & Solvency		 - - -
Liquidity Ratios		 - - -
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -63 -81
Efficiency Ratios		 - - -
Capital & Investment Metrics		 - - -
Invested Capital		 -31 -23 -6.50
Increase / (Decrease) in Invested Capital		 0.00 8.04 16
Book Value per Share		 ($103.66) $9.01 $7.59
Tangible Book Value per Share		 ($103.66) $9.01 $7.59
Total Capital		 -5.80 332 275
Total Debt		 35 8.50 2.65
Total Long-Term Debt		 8.20 2.50 0.00
Net Debt		 9.82 -346 -279
Capital Expenditures (CapEx)		 0.17 0.37 0.72
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -31 -19 -12
Debt-free Net Working Capital (DFNWC)		 -6.19 335 269
Net Working Capital (NWC)		 -33 329 267
Net Nonoperating Expense (NNE)		 30 16 16
Net Nonoperating Obligations (NNO)		 9.82 -346 -279
Total Depreciation and Amortization (D&A)		 0.16 0.17 -1.41
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($6.63) ($2.24)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 10.73M 35.93M
Adjusted Diluted Earnings per Share		 $0.00 ($6.63) ($2.24)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 10.73M 35.93M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 35.85M 44.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -34 -55 -65
Debt Service Ratios		 - - -
Payout Ratios		 - - -

Quarterly Metrics And Ratios for BioAge Labs

This table displays calculated financial ratios and metrics derived from BioAge Labs' official financial filings.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 0.00 0.00 0.00 0.00 35,848,738.00 35,850,037.00 35,850,037.00 35,850,037.00 35,855,037.00 44,379,753.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 35,848,738.00 35,850,037.00 35,850,037.00 35,850,037.00 35,855,037.00 44,379,753.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 -0.59 -0.36 -0.60 -0.56 -0.72 -0.51
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 91.04%
EBITDA Growth		 0.00% 0.00% 0.00% -96.67% - -28.40% -62.37% 7.70% - -56.12%
EBIT Growth		 0.00% 0.00% 0.00% -96.97% - -28.35% -62.23% 7.65% - -54.29%
NOPAT Growth		 0.00% 0.00% 0.00% -150.33% - -28.35% -62.23% 6.51% - -54.29%
Net Income Growth		 0.00% 0.00% 0.00% -60.05% - 0.49% -58.77% 13.82% - -72.13%
EPS Growth		 0.00% 0.00% 0.00% 23.34% - 95.36% 92.44% 91.64% - -44.44%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% - -10.79% -26.54% -7.45% - -38.49%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% -254.03% - -21.11%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 60.61% - -1,088.35%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 66.23% -14.84% - -9.94%
EBITDA Q/Q Growth		 0.00% 0.00% -19.09% -64.38% - 0.00% -50.61% 6.56% - 9.65%
EBIT Q/Q Growth		 0.00% 0.00% -19.17% -64.10% - 0.00% -50.62% 6.58% - 10.72%
NOPAT Q/Q Growth		 0.00% 0.00% -19.17% -62.09% - 0.00% -50.62% 6.58% - 10.72%
Net Income Q/Q Growth		 0.00% 0.00% -4.53% -72.35% - 0.00% -66.79% 6.46% - 14.22%
EPS Q/Q Growth		 0.00% 0.00% -2.32% 15.62% - 0.00% -66.67% 6.67% - 27.78%
Operating Cash Flow Q/Q Growth		 0.00% -84.31% -0.70% 5.39% - -237.93% -15.01% 19.66% - 14.88%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% -82.80% -12.18% - 62.83%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% - 0.00% 854.94% -243.80% - 27.77%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% - 100.00% 100.00% 100.00% - 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% - -1,130.88% -1,024.59% -1,124.20% - -924.17%
Operating Margin		 0.00% 0.00% 0.00% 0.00% - -1,133.43% -1,026.99% -1,126.58% - -915.40%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% - -1,133.43% -1,026.99% -1,126.58% - -915.40%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% - -890.97% -893.99% -982.04% - -802.78%
Tax Burden Percent		 100.00% 100.06% 100.52% 100.00% - 99.55% 100.05% 100.21% - 100.48%
Interest Burden Percent		 114.97% 101.33% 88.49% 93.42% - 78.97% 87.01% 86.99% - 87.27%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% - 0.00% -1,862.56% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% - 0.00% -1,859.67% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% - 0.00% 1,840.86% 0.00% - 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% 0.00% - -22.69% -21.71% -25.64% - -25.98%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% - -4.78% -12.32% -20.75% - -25.47%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% - -3.76% -10.72% -18.09% - -22.34%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 0.00% - -22.69% -21.71% -25.64% - -25.98%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% - -22.69% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.92 -8.97 -11 -17 -18 -12 -17 -16 -20 -18
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% - -793.40% -718.89% -788.61% - -640.78%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% -3.75% - -0.90% -2.89% -1.31% - -1.29%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -5.35% -5.35% -3.60% -5.77% -5.75% -7.24% -4.67%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% - 467.82% 304.27% 325.27% - 279.11%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% - 765.61% 822.72% 901.31% - 736.29%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% - 1,233.43% 1,126.99% 1,226.58% - 1,015.40%
Earnings before Interest and Taxes (EBIT)		 -13 -13 -15 -25 -25 -16 -25 -23 -28 -25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -13 -15 -25 -25 -16 -25 -23 -28 -26
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.23 - 0.43 0.50 0.76 - 1.96
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.23 - 0.43 0.50 0.76 - 1.96
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 - 92.90 38.33 35.63 - 72.02
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 34.82
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.03 - 0.02 0.02 0.01 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.01 - 0.00 0.00 0.00 - 0.00
Financial Leverage		 0.00 0.00 0.00 -1.03 - -1.00 -0.99 -1.03 - -1.01
Leverage Ratio		 0.00 0.00 0.00 1.08 - 1.10 1.09 1.09 - 1.07
Compound Leverage Factor		 0.00 0.00 0.00 1.00 - 0.87 0.95 0.95 - 0.93
Debt to Total Capital		 0.00% 0.00% 0.00% 3.07% - 2.20% 1.86% 1.47% - 0.30%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 1.85% - 1.87% 1.86% 1.47% - 0.30%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 1.22% - 0.33% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 96.93% - 97.80% 98.14% 98.53% - 99.70%
Debt to EBITDA		 0.00 0.00 0.00 0.00 - -0.09 -0.06 -0.05 - -0.01
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 - 3.84 3.20 3.15 - 3.71
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 - -0.01 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 - -0.12 -0.09 -0.07 - -0.02
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 - 5.47 4.56 4.49 - 5.39
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 - -0.02 0.00 0.00 - 0.00
Altman Z-Score		 0.00 0.00 0.00 0.00 - 2.45 2.79 3.98 - 23.75
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 17.63 - 13.68 13.21 11.87 - 24.76
Quick Ratio		 0.00 0.00 0.00 17.53 - 13.52 13.04 11.69 - 24.36
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 -6.44 0.00 -11 -20 -23 -36 -13
Operating Cash Flow to CapEx		 0.00% 0.00% -45,088.57% -4,895.41% - -4,075.82% -12,559.12% -72,927.27% - -92,484.62%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -16.60 - -43.60 -101.10 -152.99 - -345.22
Operating Cash Flow to Interest Expense		 0.00 -10.68 -35.62 -38.48 - -68.09 -99.35 -107.68 - -616.56
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -10.68 -35.70 -39.27 - -69.76 -100.14 -107.83 - -617.23
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 - 0.00 0.01 0.02 - 0.03
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 - 4.02 6.41 0.00 - 19.28
Inventory Turnover		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 - 1.56 3.97 7.81 - 10.09
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 - 90.81 56.98 0.00 - 18.93
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 - 90.81 56.98 0.00 - 18.93
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -11 -23 -0.40 2.98 -4.29 -6.50 -4.69
Invested Capital Turnover		 0.00 0.00 0.00 0.00 - -7.35 2.59 -0.78 - -4.05
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 -11 0.00 -0.40 2.98 6.60 16 -4.30
Enterprise Value (EV)		 0.00 0.00 0.00 -252 - -179 -144 -71 - 359
Market Capitalization		 198 198 198 73 - 135 148 211 - 743
Book Value per Share		 $0.00 $0.00 $0.00 $89.78 $9.01 $8.74 $8.22 $7.74 $7.59 $8.54
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $89.78 $9.01 $8.74 $8.22 $7.74 $7.59 $8.54
Total Capital		 0.00 0.00 0.00 324 332 320 300 282 275 380
Total Debt		 0.00 0.00 0.00 9.94 8.50 7.06 5.60 4.13 2.65 1.16
Total Long-Term Debt		 0.00 0.00 0.00 3.94 2.50 1.06 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 0.00 -325 -346 -314 -292 -282 -279 -384
Capital Expenditures (CapEx)		 0.00 0.00 0.04 0.31 0.03 0.43 0.16 0.02 0.11 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -11 -19 -13 -13 -15 -12 -7.68
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 323 335 307 284 270 269 377
Net Working Capital (NWC)		 0.00 0.00 0.00 317 329 301 279 266 267 376
Net Nonoperating Expense (NNE)		 7.70 4.02 2.89 6.08 3.38 1.42 4.22 3.97 6.05 4.49
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -325 -346 -314 -292 -282 -279 -384
Total Depreciation and Amortization (D&A)		 0.00 0.03 0.05 0.04 0.05 0.04 0.06 0.05 0.07 -0.24
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% - -926.46% -332.36% -258.86% - -74.47%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% - 21,162.99% 7,363.60% 4,570.91% - 3,656.38%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% - 20,749.48% 7,218.74% 4,501.18% - 3,645.14%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($6.70) $15.77 ($0.36) ($0.60) ($0.56) ($0.72) ($0.52)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 3.49M 10.73M 35.85M 35.85M 35.85M 35.93M 42.48M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($6.70) $15.77 ($0.36) ($0.60) ($0.56) ($0.72) ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 3.49M 10.73M 35.85M 35.85M 35.85M 35.93M 42.48M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 35.85M 35.85M 35.85M 35.85M 35.86M 44.38M 44.45M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.92 -8.97 -11 -17 -18 -12 -17 -16 -20 -18
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% - -793.40% -718.89% -788.61% - -640.78%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% - -895.04% -893.53% -979.99% - -798.92%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -5.29 -8.73 -34.47 -64.58 - -64.49 -123.24 -155.30 - -650.64
NOPAT to Interest Expense		 -2.88 -6.11 -24.13 -44.65 - -45.15 -86.27 -108.71 - -455.45
EBIT Less CapEx to Interest Expense		 0.00 -8.73 -34.55 -65.36 - -66.16 -124.03 -155.45 - -651.31
NOPAT Less CapEx to Interest Expense		 0.00 -6.11 -24.21 -45.44 - -46.82 -87.06 -108.86 - -456.12
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - -0.80%

Financials Breakdown Chart

Key Financial Trends

BioAge Labs (NASDAQ: BIOA) has shown a mix of top-line growth and ongoing cash burn across its 2025 quarters. Below are the key patterns drawn from the latest four years of quarterly data, focused on the cash flow, income statement, and balance sheet indicators most relevant to investors.

  • Revenue ramp in 2025: quarterly operating revenue grows from about 1.45M in Q1 2025 to 3.08M in Q4 2025, with Q3 2025 at ~2.05M. This suggests improving top-line activity.
  • Financing activity boosts liquidity in Q4 2025: Issuance of common equity totaled about 17.16M, contributing to a positive net financing cash flow for the quarter.
  • Net cash from financing activities turns positive in Q4 2025: +~16.0M, providing a liquidity cushion despite operating losses.
  • Liquidity remains solid into 2025: cash and equivalents run in the 215–258M range across 2025 quarters, indicating a substantial cash runway for continued R&D and operations.
  • Balance-sheet resilience: Total equity remains in the hundreds of millions (roughly 277–313M across shown periods) with zero long-term debt in the periods shown, reducing near-term financial obligations.
  • Significant accumulated deficits: Retained earnings show substantial negative levels (e.g., around -307.5M in Q4 2025), signaling long-running losses despite liquidity support.
  • Persistent net losses: Net income is negative in every quarter of 2025 (e.g., -25.94M in Q4 2025, -20.12M in Q3 2025), underscoring ongoing profitability challenges.
  • Operating cash flow remains negative: Net cash from operating activities in 2025 quarters is negative (e.g., -28.27M in Q4 2025, -16.06M in Q3 2025), indicating continued cash burn from core operations.
  • Operating expenses far exceed revenue in late 2025: Q4 2025 total operating expenses (~31.50M) far surpass revenue (~3.08M), highlighting cost-control challenges.
  • Substantial investing outflows: Consistent heavy cash outlays to investments (e.g., Purchase of Investments around -77.6M in Q1 2025, -40.3M in Q4 2025) point to aggressive investing activity that increases near-term cash burn.
05/21/26 11:54 AM ETAI Generated. May Contain Errors.

BioAge Labs Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BioAge Labs' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

BioAge Labs' net income appears to be on an upward trend, with a most recent value of -$80.61 million in 2025, rising from -$63.85 million in 2023. The previous period was -$71.11 million in 2024. Find out what analysts predict for BioAge Labs in the coming months.

BioAge Labs' total operating income in 2025 was -$92.78 million, based on the following breakdown:
  • Total Gross Profit: $9.00 million
  • Total Operating Expenses: $101.78 million

Over the last 2 years, BioAge Labs' total revenue changed from $0.00 in 2023 to $9.00 million in 2025, a change of 899,500,000.0%.

BioAge Labs' total liabilities were at $22.84 million at the end of 2025, a 34.9% decrease from 2024, and a 65.7% decrease since 2023.

In the past 2 years, BioAge Labs' cash and equivalents has ranged from $21.64 million in 2023 to $354.35 million in 2024, and is currently $188.89 million as of their latest financial filing in 2025.

Over the last 2 years, BioAge Labs' book value per share changed from -103.66 in 2023 to 7.59 in 2025, a change of -107.3%.


Related Companies

Financial statements for NASDAQ:BIOA last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel